Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 4Liver Neoplasms 2Rectal Neoplasms 1Prostatic Neoplasms 1Neoplasms 1Liver Diseases 1Hepatitis 1Glioblastoma 1Gastrointestinal Neoplasms 1Fibrosis 1Carcinoma, Squamous Cell 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms, Male 1Breast Neoplasms 1

Interventions

Sorafenib 4Blood Specimen Collection 4lenvatinib 3sintilimab 2halofantrine 2camrelizumab 2Liver Transplantation 2Antibodies 2trametinib 1toripalimab 1titanium silicide 1tislelizumab 1pembrolizumab 1ledipasvir, sofosbuvir drug combination 1genexol-PM 1gadolinium ethoxybenzyl DTPA 1fluorocholine 1bavituximab 1avatrombopag 1aumolertinib 1atezolizumab 1User-Centered Design 1Sunitinib 1Sufentanil 1Sofosbuvir 1Shadowing Technique, Histology 1Ropivacaine 1Ribavirin 1Radiotherapy 1Radiosurgery 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Liver Diseases × bavituximab × Clear all
NCT02989870 2020-06-05

Sorafenib and Bavituximab Plus SBRT in Unresectable Hepatocellular Carcinoma

H. Lee Moffitt Cancer Center and Research Institute

Phase 1 Withdrawn
Gastrointestinal

Carcinoma, Hepatocellular, Liver Diseases, Liver Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡